Form 4: Ionis Director Exercises Options, Sells Shares

Ionis Pharmaceuticals Director Joan E. Herman exercised stock options and subsequently sold a portion of the acquired shares on November 19, 2025.

Summary

• Joan E. Herman, a Director of Ionis Pharmaceuticals Inc. (IONS), engaged in multiple transactions on November 19, 2025.
• Exercised Non-Qualified Stock Options to acquire 12,000 shares of common stock at an exercise price of $40.05 per share. These options were exercisable from July 1, 2022, and expire on June 30, 2031.
• Simultaneously, sold 12,000 shares of common stock at a weighted average price of $72.1325 per share. The sales occurred in a price range from $71.985 to $72.33.
• Also exercised Non-Qualified Stock Options to acquire 32,000 shares of common stock at an exercise price of $63.9 per share. These options were exercisable from June 10, 2020, and expire on June 8, 2029.
• Simultaneously, sold 32,000 shares of common stock at a weighted average price of $72.1325 per share. The sales occurred in a price range from $71.985 to $72.33.
• Following these transactions, Joan E. Herman's direct beneficial ownership of Ionis Pharmaceuticals common stock is 46,086 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The exercise of options indicates the director is realizing value from their equity, which is a positive for the individual. The subsequent sale is a common practice for liquidity or diversification and does not inherently signal a negative outlook for the company.

Positives

• The director exercised stock options, indicating a realization of value from previously granted equity incentives.
• The sale price of $72.1325 per share is significantly higher than the exercise prices of $40.05 and $63.9, demonstrating a profitable transaction for the director.

Negatives

• The sale of 44,000 shares (12,000 + 32,000) by a director could be interpreted as a reduction in direct exposure to the company's stock, although it is often for diversification or liquidity purposes.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, such as the exercise of stock options and subsequent sale of shares, are routine occurrences in publicly traded companies, particularly in the biotechnology sector where equity compensation is common. These transactions are typically driven by individual financial planning, diversification needs, or the expiration of options, rather than necessarily signaling a change in company fundamentals or strategic direction.

Comparison to Industry Standards

• The reported transactions are standard for insider equity compensation and liquidity events within the biotech industry.
• The exercise of options and immediate sale (often referred to as a 'cashless exercise' or 'sell-to-cover') is a common practice for executives and directors to realize value from their equity awards while managing tax implications and portfolio diversification.

Stakeholder Impact

• Shareholders: The transactions represent a routine insider activity and do not typically have a significant direct impact on other shareholders, beyond the minor increase in shares available on the market from the sale.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Options, Director Transactions, Equity Sales, Beneficial Ownership